Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
Roswell Park Cancer Institute
NRG Oncology
Thomas Jefferson University
University of California, San Francisco
University of Erlangen-Nürnberg Medical School
Boston Medical Center
Ohio State University Comprehensive Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC